Explore

Trendline Trendline
Apnimed Secures $150 Million Financing to Support Potential U.S. Launch of Sleep Apnea Treatment

Apnimed Secures $150 Million Financing to Support Potential U.S. Launch of Sleep Apnea Treatment

Apnimed Secures $150 Million Financing to Support Potential U.S. Launch of Sleep Apnea Treatment
Trendline Trendline
Apnimed Secures $150 Million Financing for Sleep Apnea Drug Development

Apnimed Secures $150 Million Financing for Sleep Apnea Drug Development

Apnimed Secures $150 Million Financing for Sleep Apnea Drug Development
Trendline Trendline
FDA Approves Endospan's NEXUS Aortic Arch Stent Graft System for U.S. Market

FDA Approves Endospan's NEXUS Aortic Arch Stent Graft System for U.S. Market

FDA Approves Endospan's NEXUS Aortic Arch Stent Graft System for U.S. Market
Trendline Trendline
Dexcel Pharma USA Receives FDA Approval for Nintedanib Capsules, Expanding Treatment Options for Lung Disease

Dexcel Pharma USA Receives FDA Approval for Nintedanib Capsules, Expanding Treatment Options for Lung Disease

Dexcel Pharma USA Receives FDA Approval for Nintedanib Capsules, Expanding Treatment Options for Lung Disease
Trendline Trendline
Biocon Launches Denosumab Biosimilars in U.S. to Address Osteoporosis and Cancer-Related Bone Issues

Biocon Launches Denosumab Biosimilars in U.S. to Address Osteoporosis and Cancer-Related Bone Issues

Biocon Launches Denosumab Biosimilars in U.S. to Address Osteoporosis and Cancer-Related Bone Issues
Trendline Trendline
Biocom Warns Against Tariffs on Pharmaceuticals, Citing Risks to U.S. Drug Supply

Biocom Warns Against Tariffs on Pharmaceuticals, Citing Risks to U.S. Drug Supply

Biocom Warns Against Tariffs on Pharmaceuticals, Citing Risks to U.S. Drug Supply
Trendline Trendline
Biocom Criticizes New Section 232 Tariffs on Pharmaceuticals for Potential Supply Chain Disruptions

Biocom Criticizes New Section 232 Tariffs on Pharmaceuticals for Potential Supply Chain Disruptions

Biocom Criticizes New Section 232 Tariffs on Pharmaceuticals for Potential Supply Chain Disruptions
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Targeting Rare Disease Market

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Targeting Rare Disease Market

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Targeting Rare Disease Market
Trendline Trendline
Royal Biologics Secures FDA Clearance for Fibrinet PRF Wound Matrix to Aid Cutaneous Wound Management

Royal Biologics Secures FDA Clearance for Fibrinet PRF Wound Matrix to Aid Cutaneous Wound Management

Royal Biologics Secures FDA Clearance for Fibrinet PRF Wound Matrix to Aid Cutaneous Wound Management
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026
Trendline Trendline
FDA's New CBD Enforcement Policy Boosts MMJ International Holdings' Strategic Position

FDA's New CBD Enforcement Policy Boosts MMJ International Holdings' Strategic Position

FDA's New CBD Enforcement Policy Boosts MMJ International Holdings' Strategic Position
Trendline Trendline
Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline